<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636556</url>
  </required_header>
  <id_info>
    <org_study_id>1508151-5</org_study_id>
    <nct_id>NCT02636556</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors</brief_title>
  <official_title>Phase â…¡ Study of Concurrent Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy
      for limited advanced unresectable thymoma or thymic carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complete resection is difficult to achieve without damaging the main organs in advanced
      thymoma or thymic carcinoma. The previous trials have showed that radiotherapy was
      significantly associated with prolonged OS and chemotherapy is playing an increasing role in
      treatment of patients with advanced thymoma or thymic carcinoma. However, whether concurrent
      chemoradiotherapy is safety in advanced thymoma or thymic carcinoma is still unknown. The
      purpose of this study is to evaluate the feasibility and safety of concurrent
      chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intensity modulated radiotherapy with VP-16/Cisplatin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from registration to death as a result of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from registration to first documentation of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Thymoma and Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemoradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent chemoradiation</intervention_name>
    <description>The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w*4.</description>
    <arm_group_label>chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18~75 years old; 2.Eastern Cooperative Oncology Group performance status of 0 to 2;
        3.Pathologically or cytologically confirmed untreated thymoma or thymic carcinoma;
        4.Unresectable, limited adanced disease could be encompassed within a tolerable
        radiotherapy field; 5.Have adequate bone marrow, hepatic, and renal function; 6.Patients
        who cannot receive surgery resection; 7.Written informed consent.

        Exclusion Criteria:

          1. Distant metastases could not be encompassed within a tolerable radiotherapy field;

          2. Underwent surgery, radiotherapy or chemotherapy before entering this study ;

          3. Have other malignancy history excluding carcinoma in situ of cervix in the previous
             five years;

          4. Active clinical pulmonary infection;

          5. Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kailiang Wu, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kailiang Wu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kailiang Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>thymoma</keyword>
  <keyword>thymic carcinoma</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>inoperable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

